Observational Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 26, 2024; 12(6): 1111-1119
Published online Feb 26, 2024. doi: 10.12998/wjcc.v12.i6.1111
Clinical analysis of 12 cases of ovarian neuroendocrine carcinoma
Xiao-Yu Xing, Wei Zhang, Li-Ya Liu, Li-Ping Han
Xiao-Yu Xing, Wei Zhang, Li-Ya Liu, Li-Ping Han, Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China
Author contributions: Xing XY and Zhang W designed this study and wrote the manuscript; Liu LY participated in collection and analysis of data; Han LP reviewed and revised the manuscript; All authors read and approved the final manuscript.
Institutional review board statement: The study was reviewed and approved by The First Affiliated Hospital of Zhengzhou University Institutional Review Board (Approval No. 2023-KY-0892-002).
Informed consent statement: Consent was not needed as the study was retrospective without exposure to the patients’ data.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Ping Han, PhD, Doctor, Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe Dong Road, Erqi District, Zhengzhou 450000, Henan Province, China. fcchanlp@zzu.edu.cn
Received: November 27, 2023
Peer-review started: November 27, 2023
First decision: December 19, 2023
Revised: December 28, 2023
Accepted: January 22, 2024
Article in press: January 22, 2024
Published online: February 26, 2024

Neuroendocrine neoplasms of the female genital tract are rare.


To enhance our clinical understanding of neuroendocrine carcinoma (NEC) of the ovary.


A retrospective review was conducted on 12 patients diagnosed with NEC of the ovary, analyzing clinicopathological characteristics, treatment modalities, and survival status.


The median age at diagnosis was 34.5 years (range: 20 to 62 years). Among the 12 cases, 9 were small cell carcinoma of the ovary and 3 were large cell NEC. Five cases were stage I tumors, one case was stage IV, and six cases were stage III. Eleven patients underwent surgery as part of their treatment. All patients received adjuvant chemotherapy. Among the 12 patients, one patient received radiotherapy, and one patient with a BRCA2 mutation was administered PARP inhibitor maintenance after chemotherapy. The median progression-free survival was 13 months, and the median overall survival was 19.5 months. Four cases remained disease-free, while eight cases experienced tumor recurrence, including three cases that resulted in death due to disease recurrence.


NEC of the ovary is a rare condition that is more common in women of childbearing age and is associated with aggressive behavior and poor clinical outcomes. Surgical resection remains the mainstay of treatment, with some patients benefiting from adjuvant chemoradiation therapy.

Keywords: Neuroendocrine carcinoma, Ovary, Pathology, Treatment

Core Tip: Through the analysis and summary of 12 cases of ovarian neuroendocrine carcinoma, we found that the incidence of ovarian neuroendocrine carcinoma is low and the prognosis is poor. Surgery is the cornerstone of treatment, and some patients may benefit from comprehensive treatment.